Amneal Pharmaceuticals Profit Margin

The latest profit margin for AMRX is 3.97% as of June 2026. That compares with 0.54% in the prior-year period — up 641.2% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Amneal Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMRX's profit margin moved from 0.54% to 3.97% — a 641.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Amneal Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, AMRX currently prints 3.97% for profit margin, while the sector average sits near 21.34%. That is roughly 81.4% below the sector mean. Large gaps often invite a closer look at Amneal Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Amneal Pharmaceuticals converts resources into returns. At 3.97%, AMRX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 0.54% in the prior-year period — up 641.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AMRX's profit margin (3.97%), review year-over-year change from 0.54%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.